Health science reports · 2025
The Combination Therapy With Sorafenib in Therapeutic Strategy of Acute Myeloid Leukemia. Is It Promising? A Narrative Review.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shamahmood Mobina Nakhaei, Miri Abolfazl, Mezginejad Fatemeh
Аннотация
BACKGROUND AND AIMS: Acute myeloid leukemia (AML) is the most common acute leukemia, which is associated with high morbidity and mortality, and its incidence rate is increasing. Despite tremendous advancements in AML treatment, managing the condition is still challenging. Receptor kinase inhibitors like sorafenib have recently raised concerns about monotherapy, and combination treatments are now being investigated as a potential therapeutic avenue. To classify medications taken in conjunction with sorafenib and analyze their combined effects, we reviewed the prior research findings.
METHODS: A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers.
RESULTS: Complete remission (CR) in the combination of sorafenib with "cytarabine and idarubicin", "Vorinostat and Bortezomib, Clofarabine", "Fludarabine and Busulfan", "5-azacytidine" and "Quizartinib, Midostaurin and Giltertinib" respectively "99% and 94%", "27% and 3%", 66.6%, "45%, 26%, 16%", "71% and 52%". Furthermore, the overall survival (OS) values for the combination of sorafenib with "Quizartinib, Midostaurin, and Giltertinib", "cytarabine, daunorubicin" and "5-azacitidine" were "80%" "62% 45%", and 24%, respectively.
CONCLUSION: Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.
METHODS: A thorough literature search utilizing several databases, including PubMed, Google Scholar, Scopus, Embase, and Cochrane, yielded 78 relevant articles until October 2023. Search terms including AML, combination, and Sorafenib were utilized during the database search to find relevant papers.
RESULTS: Complete remission (CR) in the combination of sorafenib with "cytarabine and idarubicin", "Vorinostat and Bortezomib, Clofarabine", "Fludarabine and Busulfan", "5-azacytidine" and "Quizartinib, Midostaurin and Giltertinib" respectively "99% and 94%", "27% and 3%", 66.6%, "45%, 26%, 16%", "71% and 52%". Furthermore, the overall survival (OS) values for the combination of sorafenib with "Quizartinib, Midostaurin, and Giltertinib", "cytarabine, daunorubicin" and "5-azacitidine" were "80%" "62% 45%", and 24%, respectively.
CONCLUSION: Accordingly, several studies suggest that sorafenib's anticancer effectiveness may be enhanced with chemotherapy drugs.